Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a corporate overview at the Eyecelerator conference on September 29, 2022, as part of the Annual Meeting of the American Academy of Ophthalmology (AAO), the world`s largest association of eye physicians and surgeons.

“We are pleased to highlight the breadth of our suprachoroidal space (SCS®) platform across ophthalmic indications,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. “There are multiple upcoming catalysts related to our internal CLS-AX program and from our development and commercialization partners. In November of this year, we plan to report data from all four cohorts of our OASIS Phase 1/2a clinical trial of CLS-AX in patients with neovascular age-related macular degeneration (wet AMD). We believe this data will provide more insight into the potential benefits of combining pan-VEGF inhibition from the highly potent tyrosine kinase inhibitor, axitinib, with targeted delivery to affected chorioretinal tissues utilizing our proprietary SCS Microinjector^®.”

Eyecelerator @ AAO 2022 Retina Showcase Presentation
Presenting Company Showcase: Retina, Therapeutics, and Technology + Devices
Date/Time: Thursday, September 29, 2022, 2:05 PM CDT
Location: McCormick Place Convention Center, Chicago, IL
Presenter: Dr. Thomas A. Ciulla, Chief Medical Officer and Chief Development Officer